ES2074981T3 - Uso de derivados heterociclicos en el tratamiento de trastornos cognoscitivos. - Google Patents

Uso de derivados heterociclicos en el tratamiento de trastornos cognoscitivos.

Info

Publication number
ES2074981T3
ES2074981T3 ES87311079T ES87311079T ES2074981T3 ES 2074981 T3 ES2074981 T3 ES 2074981T3 ES 87311079 T ES87311079 T ES 87311079T ES 87311079 T ES87311079 T ES 87311079T ES 2074981 T3 ES2074981 T3 ES 2074981T3
Authority
ES
Spain
Prior art keywords
treatment
disorders
cognoscitive
cyclic derivatives
hetero cyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES87311079T
Other languages
English (en)
Inventor
Michael Brian Tyers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB868630074A external-priority patent/GB8630074D0/en
Priority claimed from GB868630077A external-priority patent/GB8630077D0/en
Priority claimed from GB868630076A external-priority patent/GB8630076D0/en
Priority claimed from GB878707175A external-priority patent/GB8707175D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ES2074981T3 publication Critical patent/ES2074981T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

ESTA INVENCION SE REFIERE AL EMPLEO DE COMPUESTOS QUE ACTUAN COMO ANTAGONISTAS DE 5-HIDROXITRIPTAMINA (5-HT) EN RECEPTORES DE 5-HT3, PARA EL TRATAMIENTO DE DESORDENES DE LA COGNICION TALES COMO DISMINUCION DE LA ATENCION Y DE LA MEMORIA Y ESTADOS DEMENCIALES.
ES87311079T 1986-12-17 1987-12-16 Uso de derivados heterociclicos en el tratamiento de trastornos cognoscitivos. Expired - Lifetime ES2074981T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB868630074A GB8630074D0 (en) 1986-12-17 1986-12-17 Medicaments
GB868630077A GB8630077D0 (en) 1986-12-17 1986-12-17 Medicaments
GB868630076A GB8630076D0 (en) 1986-12-17 1986-12-17 Medicaments
GB878707175A GB8707175D0 (en) 1987-03-25 1987-03-25 Medicaments

Publications (1)

Publication Number Publication Date
ES2074981T3 true ES2074981T3 (es) 1995-10-01

Family

ID=27449858

Family Applications (1)

Application Number Title Priority Date Filing Date
ES87311079T Expired - Lifetime ES2074981T3 (es) 1986-12-17 1987-12-16 Uso de derivados heterociclicos en el tratamiento de trastornos cognoscitivos.

Country Status (7)

Country Link
US (1) US4985437A (es)
EP (3) EP0551963A3 (es)
JP (1) JP2608079B2 (es)
AT (2) ATE124865T1 (es)
DE (2) DE3752062T2 (es)
ES (1) ES2074981T3 (es)
GR (1) GR3017369T3 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988003801A1 (en) * 1986-11-21 1988-06-02 Glaxo Group Limited Medicaments for treatment or prevention of withdrawal syndrome
US5198447A (en) * 1986-11-21 1993-03-30 Glaxo Group Limited Medicaments
GB8820651D0 (en) * 1988-09-01 1988-10-05 Glaxo Group Ltd Medicaments
AU5650890A (en) * 1989-05-24 1990-12-18 Nippon Shinyaku Co. Ltd. Indole derivatives and medicine
US5171745A (en) * 1990-07-13 1992-12-15 Du Pont Merck Pharmaceutical Company Method of treating neurological dysfunction using neutrotransmitter enhancers
US5342845A (en) * 1990-08-31 1994-08-30 Nippon Shinyaku Company Limited Indole derivatives and drugs
HU211081B (en) * 1990-12-18 1995-10-30 Sandoz Ag Process for producing indole derivatives as serotonin antagonists and pharmaceutical compositions containing the same
EP0492020A1 (en) * 1990-12-21 1992-07-01 Merrell Dow Pharmaceuticals Inc. Use of certain esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3(4H)-one and related compounds for treating cognitive disorders
IT1250629B (it) * 1991-07-04 1995-04-21 Boehringer Ingelheim Italia Uso dei derivati dell'acido benzimidazolin-2-oxo-1-carbossilico.
JPH08507514A (ja) * 1993-03-08 1996-08-13 藤沢薬品工業株式会社 脳血管性疾患を治療または予防するための薬物
GB9412995D0 (en) * 1994-06-28 1994-10-26 Prendergast Kenneth F Safety enhancing pharmaceutical compositions of an active indazole
AR036041A1 (es) * 2001-06-12 2004-08-04 Upjohn Co Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen
AR036040A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
EP1425286B1 (en) * 2001-09-12 2007-02-28 Pharmacia & Upjohn Company LLC Substituted 7-aza-[2.2.1]bicycloheptanes for the treatment of diseases
EP1432707B1 (en) 2001-10-02 2012-03-28 Pharmacia & Upjohn Company LLC Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
US6849620B2 (en) 2001-10-26 2005-02-01 Pfizer Inc N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
BR0307782A (pt) * 2002-02-19 2005-01-04 Upjohn Co Compostos azabiciclo para o tratamento de doença
US6858613B2 (en) * 2002-02-19 2005-02-22 Pfizer Inc. Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease
WO2003072578A1 (en) * 2002-02-20 2003-09-04 Pharmacia & Upjohn Company Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity
CA2503786A1 (en) * 2002-11-01 2004-05-13 Pharmacia & Upjohn Company Llc Compounds having both alpha7 nicotinic agonist activity and 5ht, antagonist activity for treatment of cns diseases
GB201421161D0 (en) * 2014-11-28 2015-01-14 Ge Healthcare As Metal complex formulations

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2531083B1 (fr) * 1982-06-29 1986-11-28 Sandoz Sa Nouveaux derives de la piperidine, leur preparation et leur utilisation comme medicaments
JPS5936675A (ja) * 1982-07-13 1984-02-28 サンド・アクチエンゲゼルシヤフト 二環性複素環式カルボン酸アザビシクロアルキルエステルまたはアミド
FR2557110B1 (fr) * 1983-12-23 1989-11-24 Sandoz Sa Nouveaux derives d'amines cycliques, leur preparation et leur utilisation comme medicaments
ATE86110T1 (de) * 1984-12-20 1993-03-15 Sandoz Ag Behandlung von gastrointestinalkrankheiten durch anwendung von 5-ht3-antagonisten.
CH667657A5 (de) * 1985-01-07 1988-10-31 Sandoz Ag Carbocyclische und heterocyclische carbonylmethylen- und methylpiperidine und -pyrrolidine.
US4605652A (en) * 1985-02-04 1986-08-12 A. H. Robins Company, Inc. Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes
EP0385517B1 (en) * 1985-03-14 1993-04-14 BEECHAM GROUP plc Medicaments for the treatment of emesis
US4624961A (en) * 1985-04-17 1986-11-25 A. H. Robins Company, Incorporated Method for enhancing memory or correcting memory deficiency with arylamidopyrazolidines and arylamidodiazabicycloalkanes
DE3650772T2 (de) * 1985-04-27 2003-04-03 F. Hoffmann-La Roche Ag, Basel Derivate von Indazole-3-carboxamide und -3-carboxylsäure
DE3687980T2 (de) * 1986-01-07 1993-06-17 Beecham Group Plc Indolderivate mit einer azabicyclischen seitenkette, verfahren zu ihrer herstellung, zwischenprodukte und pharmazeutische zusammensetzungen.
HU895334D0 (en) * 1986-07-30 1990-01-28 Sandoz Ag Process for the preparation of nasal pharmaceutical compositions
DE3801659A1 (de) * 1988-01-21 1989-07-27 Boehringer Ingelheim Kg Tetrahydropyridin - derivate
CA1332151C (en) * 1988-01-28 1994-09-27 Roman Amrein Use of a benzamide to treat cognitive disorder
DE68912822T2 (de) * 1988-05-16 1994-06-09 Searle & Co 2-Amino-4,5-methylenadipinsäure-Verbindungen für die Behandlung von CNS-Erkrankungen.
YU150489A (sh) * 1989-08-10 1992-12-21 W.L. Gore & Co. Gmbh. Uređaj za ispitivanje odevnih predmeta na nepromočivost
WO1991005559A1 (en) * 1989-10-16 1991-05-02 Hem Research, Inc. Diagnosis and treatment of neuro-cognitive disorders associated with systemic immunological malfunction
EP0456519B1 (en) * 1990-05-11 1994-07-13 Sankyo Company Limited Piperidyloxy- and quinuclidinyloxy- isoxazole derivatives, their preparation and their therapeutic use

Also Published As

Publication number Publication date
US4985437A (en) 1991-01-15
JP2608079B2 (ja) 1997-05-07
EP0551963A3 (en) 1993-09-01
EP0279990B1 (en) 1995-07-12
DE3752062T2 (de) 1997-09-11
EP0559297B1 (en) 1997-05-07
EP0551963A2 (en) 1993-07-21
DE3751404T2 (de) 1995-12-21
EP0279990A2 (en) 1988-08-31
EP0279990A3 (en) 1990-11-28
ATE152623T1 (de) 1997-05-15
DE3752062D1 (de) 1997-06-12
DE3751404D1 (de) 1995-08-17
EP0559297A1 (en) 1993-09-08
GR3017369T3 (en) 1995-12-31
ATE124865T1 (de) 1995-07-15
JPS63277623A (ja) 1988-11-15

Similar Documents

Publication Publication Date Title
GR3017369T3 (en) Use of heterocyclic derivatives in the treatment of cognitive disorders.
EA199700156A1 (ru) Производные индола как антагонисты рецептора 5-нт
FI931370A0 (fi) Kvaeve innehaollande analoger av icke-aromatiska heterocykliska foereningar med en fusionerad ring
ATE162521T1 (de) 3-aminopiperidine derivate und verwandete stickstoff enthaltende heterocyclische verbindungen
BR9206500A (pt) Heterociclos contendo, nitrogênio tricíclico condensado como antagonistas de substancia receptora P
SE8704746L (sv) Tricykliska ketoner
DE3772789D1 (de) Halogen enthaltende heterozyklische verbindungen und diese enthaltende fluessigkristalline zusammensetzungen.
BR9106665A (pt) Derivados de quinuclidina
CA2123403A1 (en) Acyclic ethylenediamine derivatives as substance p receptor antagonists
NO964236L (no) Anvendelse av serotonin-antagonister (5HT3) for behandling av fibromyalgi
DE69129009D1 (de) Indole Derivate als Serotonin-Antagonisten
DE3788057D1 (de) Verwendung von heterocyclischen Verbindungen zur Behandlung von Depressionen.
GB8518658D0 (en) Medicaments
ZA857270B (en) Tetralin derivatives,their preparation and their use
DK0556329T3 (da) Substituerede piperaziner som midler til behandling af centralnervesystemet
NO871861D0 (no) Fremgangsmaate for fremstilling av nye dopamin beta-hydroxylase inhibitorer.
ATE182467T1 (de) Verwendung von antagonisten oder partiellen agonisten am 5-ht 1a-rezeptor zur behandlung und prävention von kognitiven störungen
ATE95704T1 (de) Anwendung heterozyklischer derivate zur herstellung von arzneimitteln.
FI905957A0 (fi) Foerfarande foer framstaellning av substituerade cyklohexener, som verkar pao det centrala nervsystemet.
BG103089A (en) Indoline derivatives useful as 5-ht-2c-receptor antagonists
DE68918449D1 (de) Siliziumverbindungen zur behandlung von knochen.
ATE81016T1 (de) Anwendung heterozyklischer dervate zur herstellung von arzneimitteln.
ES2016857B3 (es) Derivados de 4 - feniltiazol.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 279990

Country of ref document: ES